A Double-Blind Placebo-Controlled Study of the Effects of the Bisphosphonate Risedronate on Bone Mass in Patients with Inflammatory Bowel Disease
暂无分享,去创建一个
[1] M. Dougados,et al. Bone loss in patients with inflammatory bowel disease: A prospective study , 1995, Osteoporosis International.
[2] D. Jaspersen,et al. [Gastrointestinal side effects of drugs]. , 2004, Deutsche medizinische Wochenschrift.
[3] W. Kratzer,et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate , 2003, Alimentary pharmacology & therapeutics.
[4] R. Lindsay,et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. , 2002, Mayo Clinic proceedings.
[5] A. Devine,et al. Effects of vitamin D metabolites on intestinal calcium absorption and bone turnover in elderly women. , 2002, The American journal of clinical nutrition.
[6] S. Dhaliwal,et al. Precision error of fan-beam dual X-ray absorptiometry scans at the spine, hip, and forearm. , 2000, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[7] M. Staun,et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. , 2000, Gastroenterology.
[8] S. Laurberg,et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis , 2000, Gut.
[9] S. Wallach,et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 1999, Arthritis and rheumatism.
[10] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[11] W. Fries,et al. Evolution of osteopenia in inflammatory bowel disease , 1999, American Journal of Gastroenterology.
[12] Jacques P. Brown,et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .
[13] Z. Tulassay,et al. Altered Bone Metabolism in Inflammatory Bowel Disease , 1998, American Journal of Gastroenterology.
[14] Jacques P. Brown,et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. , 1998, The New England journal of medicine.
[15] I. Forgacs,et al. Reduced bone density in patients with inflammatory bowel disease. , 1997, Gut.
[16] M. Manns,et al. Altered bone metabolism in inflammatory bowel disease. , 1997, The American journal of gastroenterology.
[17] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[18] C. Bernstein,et al. A randomized, placebo‐controlled trial of calcium supplementation for decreased bone density in corticosteroid‐using patients with inflammatory bowel disease: a pilot study , 1996, Alimentary pharmacology & therapeutics.
[19] R. Prince,et al. Comparison of biochemical markers of bone turnover in paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross‐links , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] P. Tugwell,et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. , 1996, The Journal of rheumatology.
[21] R. Recker,et al. Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .
[22] T. Karttunen,et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. , 1995, Gut.
[23] Deborah Kerr,et al. The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] P. Ferenci,et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. , 1995, European journal of gastroenterology & hepatology.
[25] M. Dougados,et al. Metabolic bone assessment in patients with inflammatory bowel disease. , 1995, Gastroenterology.
[26] J. Sayre,et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] D. Clements,et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. , 1993, Gut.
[28] R. Prince,et al. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. , 1992, Nephron.
[29] W. Mysiw,et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[30] R. Devlin,et al. Human lactation: Forearm trabecular bone loss, increased bone turnover, and renal conservation of calcium and inorganic phosphate with recovery of bone mass following weaning , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] J. Compston,et al. Osteoporosis in patients with inflammatory bowel disease. , 1987, Gut.
[32] P. Price,et al. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. , 1980, Proceedings of the National Academy of Sciences of the United States of America.